TuHURA is a clinical-stage, oncology-focused biotechnology company advancing innate immune agonists, checkpoint inhibitors & antibody-drug conjugates (ADCs). It offers the IFx platform technology featuring the IFx-2.0 tumoral injection delivery approach for Merkel cell carcinoma (MCC) & the IFx-3.0 intravenous delivery approach for lymphoma. IFx encodes a bacterial protein to be expressed in cancer cells, activating the innate immune system & subsequent cascade that may eliminate the tumor. Other assets include an anti-VISTA recently acquired from Kineta & the ADC ?-opioid receptor which may be used to treat blood cancers. IFx-2.0 uses pDNA to encode the production of Emm55 on cancer cells to elicit an immune response. A pivotal trial is planned for 1H:25, with a plan for FDA approval in 24 months using accelerated regulatory pathways & support from Project Frontrunner. Other assets in the portfolio may also advance quickly with supportive early data. TuHURA recently reverse merged into a shell company and raised $36 million in 2024 to support its pipeline of products. Additional capital raises and partnerships with established biopharma companies are expected. Initial clinical studies target rare and blood cancers, future opportunity lies in oncology using combinations with other immunotherapies.
